Figure 5.
Neutralization of SARS-CoV-2 Omicron variants by pooled human sera from post-third-dose monovalent mRNA vaccine recipients. Post-third-dose sera pool with medium range spike-specific antibody titers (159–3015 BAU/mL) was generated from five volunteers (no prior SARS-CoV-2 infection) who received three doses of the original mRNA monovalent vaccine (Moderna or Pfizer-BioNTech). Various SARS-CoV-2 Omicron variants with additional spike mutations were analyzed using this post-third-dose medium sera pool. All viruses were isolated from clinical specimens. Bars represent GMT with geometric SD from 2–6 independent repeats of virus with the same spike protein sequence. Significance relative to 614D, BA.1, BA.2, BA.4/5 or BA.2.75 was determined by one-way ANOVA with Dunnett correction on log transformed neutralization titers. p values are displayed as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 and not significant (ns) p > 0.05. Significance to 614D was not displayed as all Omicron variants analyzed had **** p ≤ 0.0001. GMT and fold changes compared to 614D are displayed on the side. The dashed line represents the limit of detection at FRNT50 of 10. * BA.2.3.20 = BA.2 + M153T + N164K + H245N + G257D + K444R + N450D + L452M + N460K + A484R + R493Q.